Neurology

Primary care clinicians are generally the first clinical contact for older adults with early signs of dementia. Our survey uncovered 5 primary challenges to being in that role.

The survey of primary care clinicians found that a majority do conduct screening for MCI, but that time is an issue, guidelines are few, and low levels of confidence persist.

Cycling and mixed cycling were associated with a reduced risk of all-cause dementia, including of young onset, as well as increased hippocampal volume.

A study reveals low clinician engagement in digital cognitive assessments for dementia in primary care, highlighting workflow and other barriers to early detection.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

For every 10% increase in energy from high-quality carbohydrates, the odds of healthy aging rose by 31%, according to an analysis of data from the Nurse's Health Study.

Senate hearing reveals tensions between scientific consensus and HHS Secretary Kennedy's claims on Alzheimer research funding and priorities.

ESOC 2025: New research reveals that combined oral contraceptive use significantly increases the risk of cryptogenic stroke in young women, urging careful assessment by clinicians.

Adults with early AD who were treated with lecanemab in a specialty memory clinic experienced adverse events comparable to those seen in clinical trials.

The diagnostic is designed to help clinicians determine the likelihood of cerebral β-amyloid plaque deposition, one of the neuropathologic hallmarks of AD.

Any increase in lipoprotein(a) levels was linked to increased risk of myocardial infarction and stroke; women and Black adults are most likely to be affected.

Primary care clinicians are on the frontline of detecting early cognitive decline. Help us understand your challenges by taking this short survey.

The new findings are contrary to previous research that found family history of AD increases desire for testing and support the "right not to know."

The only approved DHE nasal powder addresses persistent limitations of existing DHE formulations, including liquid nasal sprays and injectables, Satsuma stated.

Occasional trouble finding a word reflects typical age-related brain changes; the changes that cause a person to refer to a watch as a "hand clock" are not the same.

US adults want to know if they have Alzheimer disease and early, when treatment may slow it down; they are even willing to risk participation in trials of new drugs. Read more.

Biomarkers in a pattern characteristic of Alzheimer pathology were identified in unspecified dementia, Parkinson dementia, and frontotemporal dementia.

Subgroup analyses found no significant difference in efficacy based on change in therapeutic action (ie, CGRP vs its receptor), doses, or intertreatment interval.

Authors found a dose-response relationship between MetS and dementia onset in the 4th decade; in those with all 5 components, risk of dementia was increased by 77%.

The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.

Interventions to protect or improve auditory health across the lifespan could be a cost-effective means of slowing the rapid rise of dementia in the US, authors wrote.

CT-132 is a 12-week app-based intervention that uses validated behavioral techniques to modulate labile brain circuitry involved in migraine, according to Click Therapeutics.

Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.

ACP 2025: Dr Press discusses how the Penn Integrated Care model equips primary care physicians to manage mental health conditions more effectively while reducing burnout.

Your daily dose of the clinical news you may have missed.

In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.

Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.

Your daily dose of the clinical news you may have missed.